| Contraception |
1 |
1 |
| Acne |
0 |
0.95 |
| Rosacea |
0 |
0.84 |
| Adolescent Medicine |
0 |
0.99 |
| Skin and Soft Tissue Infection |
0 |
0.63 |
| Isotretinoin |
0 |
0.98 |
| Pediatric Dermatology |
0 |
0.4 |
| Child |
0 |
0.38 |
| Emergency Contraception |
0 |
0.31 |
| Hormonal Therapy |
0 |
0.19 |
| Intrauterine Device |
0 |
0.19 |
| Pregnancy |
0 |
0.17 |
| Adverse Effects |
0 |
0.13 |
| Drug Interaction |
0 |
0.13 |
| Heart |
0 |
0.13 |
| Patient Safety |
0 |
0.13 |
| Valvular Heart Disease |
0 |
0.13 |
| Liver Tumor |
0 |
0.11 |
| Hypertension |
0 |
0.1 |
| Polycystic Ovary Syndrome |
0 |
0.09 |
| Metabolic Syndrome |
0 |
0.08 |
| Infertility Female |
0 |
0.07 |
| Abortion |
0 |
0.06 |
| ACE Inhibitor |
0 |
0.06 |
| Adherence |
0 |
0.06 |
| Aura |
0 |
0.06 |
| Blood |
0 |
0.06 |
| Board Certification |
0 |
0.06 |
| Body Mass Index |
0 |
0.06 |
| Brain |
0 |
0.06 |
| Breast |
0 |
0.06 |
| Clinical Guidelines |
0 |
0.06 |
| Diet |
0 |
0.06 |
| Estrogen |
0 |
0.06 |
| Hirsutism |
0 |
0.06 |
| Infertility |
0 |
0.06 |
| Insulin Resistance |
0 |
0.06 |
| Liver |
0 |
0.06 |
| Lupus |
0 |
0.06 |
| Metabolism |
0 |
0.06 |
| Minnesota |
0 |
0.06 |
| Ovary |
0 |
0.06 |
| Premenstrual Syndrome |
0 |
0.06 |
| Progestin |
0 |
0.06 |
| Receptors |
0 |
0.06 |
| Residency |
0 |
0.06 |
| Retinoids |
0 |
0.06 |
| Risk Evaluation and Mitigation Strategies |
0 |
0.06 |
| Seizure |
0 |
0.06 |
| Students |
0 |
0.06 |
| Thrombosis |
0 |
0.06 |
| Tumor |
0 |
0.06 |